

Egypt Breast Cancer Diagnostics Market, By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application (Screening Diagnostic & Predictive, Prognostic, Research), By End User (Hospitals & Clinics, Diagnostic Centers, Medical Laboratories, Others) By Region, Competition Forecast & Opportunities, 2028

<https://marketpublishers.com/r/ED04F1A9D625EN.html>

Date: August 2023

Pages: 78

Price: US\$ 3,500.00 (Single User License)

ID: ED04F1A9D625EN

Abstracts

Egypt Breast Cancer Diagnostics Market, 2028 is expected to grow at an impressive rate during the forecast period, 2024-2028.

The Egypt Breast Cancer Diagnostics Market growth is attributed to the factors such as increasing breast cancer prevalence, the growing screening and diagnosis of breast cancer in women, technological advancement in the testing techniques for faster diagnosis among women in the country.

Furthermore, growing advancement in screening techniques is influencing the market for growth as it helps in early diagnosis and treatment of breast cancer. Also, growing awareness of breast cancer screening, management suggestions and assessing misconceptions play a role in utilizing relevant health services at a prior time for early diagnosis and management of the cancer.

In the country, COVID-19 affected cancer patients regarding the availability of healthcare access, as screenings, diagnosis, and commencement of treatment in specialized centers were affected by the pandemic.

The disease diagnosis was highly affected by the stages at which the breast cancer was detected and is further subjected to treatment options in the country and is thereby driving the breast cancer diagnostics in the country.

According to the Globocan 2020, Egypt has total 134 632 new cases of cancer in the country. Breast cancer being the second most prevalent type of cancer among women in the country with 22038 new cases of cancer and holding about 32.4% of total new cancer cases among women in the country.

Breast cancer is the most common cancer among women in Egypt, followed by colorectal, cervical, and ovarian cancer. The increasing incidence of cancer among women in Egypt is attributed to several factors.

One of the main factors contributing to the growing incidence of cancer among women in Egypt is changes in lifestyle and diet. The adoption of a Westernized lifestyle, including increased consumption of high-fat and processed foods, and a sedentary lifestyle, has been linked to an increased risk of cancer. In addition, smoking is a common risk factor for many types of cancer, and a significant percentage of women in Egypt are smokers. According to WHO's Eastern Mediterranean Health Journal's data, In 2019, Egypt has one of the highest rates of tobacco use in the Eastern Mediterranean region, also approximately half of Egyptian men currently smoke cigarettes or other tobacco products – maximum of them smoke daily – compared with 0.2% of women.

Another contributing factor is the lack of access to preventative measures and early detection services. Many women in Egypt do not have access to regular screening programs, and cancer is often detected at an advanced stage, which reduces the chances of successful treatment and survival.

Other factors include genetic predisposition, exposure to environmental toxins, and limited access to healthcare. Environmental toxins such as asbestos, vinyl chloride, benzene, radon, and arsenic are chemicals which cause a risk for breast cancer. Women in rural areas and those with lower socioeconomic status are at higher risk of cancer due to limited access to healthcare.

Many organizations and healthcare providers in the country are working to raise awareness about breast cancer and the importance of regular screenings. This has led to an increase in the number of women seeking screening services and has helped to

detect breast cancer at an earlier stage, when it is more treatable.

Growing Technological Advancement In Diagnostic Tools

New imaging techniques, such as digital mammography and breast MRI, have improved the accuracy of breast cancer detection and have made it easier to detect breast cancer in its early stages. These technological advancements have led to the development of more effective treatment options, such as targeted therapies and immunotherapy.

One such technological advancement is digital mammography, which has become the standard method for breast cancer screening in Egypt. Digital mammography uses computer technology to produce high-quality images of breast tissue, making it easier for radiologists to detect and diagnose breast cancer. This method is less time-consuming and more accurate than traditional mammography, which uses film to capture images.

Another technological advancement in breast cancer diagnostics is breast MRI (magnetic resonance imaging), which is an imaging technique that uses powerful magnets and radio waves to create detailed images of the breast tissue. Breast MRI is used in cases where mammography is not sufficient or where the results are inconclusive. This method has proven to be highly effective in detecting breast cancer in its early stages.

In addition to imaging techniques, there have been significant advancements in molecular diagnostic tools for breast cancer in Egypt. These tools can identify specific gene mutations and biomarkers associated with breast cancer, allowing for more targeted and personalized treatment options. One such tool is the Oncotype DX test, which uses a genetic test to determine the likelihood of breast cancer recurrence and the potential benefits of chemotherapy.

Artificial intelligence (AI) and machine learning technologies are being increasingly used in breast cancer diagnostics in Egypt. These technologies can help radiologists and healthcare providers analyze large amounts of data and identify patterns and trends that may not be immediately apparent to the human eye.

Growing Awareness Among Women

There is a need for increased awareness about breast cancer and the importance of early detection and treatment in Egypt. Many organizations and healthcare providers in

the country are working to address this issue, including the Breast Cancer Foundation of Egypt and the National Cancer Institute. These organizations offer free or low-cost mammography screening programs and educational campaigns to raise awareness about breast cancer and the importance of early detection.

The government has launched several programs aimed at improving access to cancer care and treatment, including the establishment of specialized cancer centers and the expansion of screening programs. The government has increased funding for cancer research, which has led to the development of new diagnostic tools and treatment options.

According to Globocan 2020, Breast cancer is a significant health concern in Egypt, with breast cancer being the most common cancer in women (~32.4%) in the country. The country is focused on preventing, diagnosing, treating, and managing breast cancer, with many organizations and healthcare providers working to provide support and care to those affected by the disease.

The Breast Cancer Foundation of Egypt (BCFE) provides facilities such as free mammograms, ultrasounds, and biopsies to women who cannot afford them, and provides financial support to breast cancer patients to help cover the cost of treatment. Similar to BCFE, there are many healthcare providers in Egypt that specialize in breast cancer diagnosis and treatment. The National Cancer Institute (NCI) in Cairo is one such provider, offering a range of services including mammography, breast ultrasound, breast MRI, and breast biopsy. The NCI provides chemotherapy, radiation therapy, and surgery for breast cancer patients.

Another organization is the Egyptian Society of Breast Diseases and Surgery (ESBDS). The ESBDS is a professional organization that brings together healthcare providers who specialize in the diagnosis and treatment of breast cancer. The ESBDS provides education and training to its members and advocates for improved breast cancer care in Egypt.

Moreover, access to care can be limited for some women, particularly those living in rural areas, and there is a shortage of trained healthcare providers and resources in many parts of the country. There is a need for increased awareness about breast cancer and the importance of early detection and treatment.

Market Segmentation

Egypt Breast Cancer Diagnostics Market is segmented based on the product, type, application, end user, and region. Based on product, the market is segmented into platform-based and instrument-based. Based on type, the market is segmented into imaging, biopsy, genomic tests, and blood tests. Based on application, the market is further fragmented into screening diagnostic & predictive, prognostic, and research. Based on end-users, the market is further segmented into hospitals & clinics, diagnostic centers, medical laboratories, and others.

Market Players

AstraZeneca, Pfizer Inc, Sanofi , Bristol Myers Squibb, Merck & Co, Novartis AG, Eli Lilly and Company, Fresenius Kabi, GlaxoSmithKline Egypt, GE Healthcare Egypt, etc. are some of the leading companies operating in the Egypt breast cancer diagnostics market.

Report Scope:

In this report, Egypt Breast Cancer Diagnostics Market, 2028, has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Egypt Breast Cancer Diagnostics Market, By Product

Platform-based

Instrument-based

Egypt Breast Cancer Diagnostics Market, By Type

Imaging

Biopsy

Genomic Tests

Blood Tests

Egypt Breast Cancer Diagnostics Market, By Application

Screening

Diagnostic & Predictive

Prognostic

Research

Egypt Breast Cancer Diagnostics Market, By End User

Hospitals & Clinics

Diagnostic Centers

Medical Laboratories

Others

Egypt Breast Cancer Diagnostics Market, By Region:

Alexandria

Suze Canal

Asyut region

Delta

Greater Cairo & Upper North Region

South upper region

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Egypt Breast Cancer Diagnostics Market, 2028.

Available Customizations:

Egypt Breast Cancer Diagnostics Market, By Product (Platform-based, Instrument-based), By Type (Imaging, Biops...

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. EGYPT BREAST CANCER DIAGNOSTICS MARKET, 2028, OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Product (Platform-based, Instrument-based)
 - 5.2.2. By Type (Imaging, Biopsy, Genomic Tests, Blood Tests)
 - 5.2.3. By Application (Screening Diagnostic & Predictive, Prognostic, Research)

5.2.4. By End-use (Hospitals & Clinics, Diagnostic Centers, Medical Laboratories, Others)

5.2.5. By Company (2022)

5.2.6. By Region

5.3. Product Market Map

6. EGYPT PLATFORM- BASED BREAST CANCER DIAGNOSTICS MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type

6.2.2. By Application

6.2.3. By End User

7. EGYPT INSTRUMENT-BASED BREAST CANCER DIAGNOSTICS MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type

7.2.2. By Application

7.2.3. By End User

8. MARKET DYNAMICS

8.1. Drivers

8.2. Challenges

9. MARKET TRENDS & DEVELOPMENTS

9.1. Recent Developments

9.2. Mergers & Acquisitions

9.3. Product Developments

10. POLICY & REGULATORY LANDSCAPE

11. EGYPT ECONOMIC PROFILE

12. COMPETITIVE LANDSCAPE

- 12.1. Business Overview
- 12.2. Company Snapshot
- 12.3. Products & Services
- 12.4. Financials (In case of listed companies)
- 12.5. Recent Developments
- 12.6. SWOT Analysis
 - 12.6.1. AstraZeneca
 - 12.6.2. Pfizer Inc
 - 12.6.3. Sanofi
 - 12.6.4. Bristol Myers Squibb
 - 12.6.5. Merck & Co
 - 12.6.6. Novartis AG
 - 12.6.7. Eli Lilly and Company
 - 12.6.8. Fresenius Kabi
 - 12.6.9. GlaxoSmithKline Egypt
 - 12.6.10. GE Healthcare Egypt

13. STRATEGIC RECOMMENDATIONS

14. ABOUT US & DISCLAIMER

I would like to order

Product name: Egypt Breast Cancer Diagnostics Market, By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application (Screening Diagnostic & Predictive, Prognostic, Research), By End User (Hospitals & Clinics, Diagnostic Centers, Medical Laboratories, Others) By Region, Competition Forecast & Opportunities, 2028

Product link: <https://marketpublishers.com/r/ED04F1A9D625EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ED04F1A9D625EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970